In this context, pembrolizumab (a monoclonal antibody against PD1 receptor) is a useful treatment for platinum-ineligible metastatic bladder cancer that shows an increased PD-L1 expression (>10%) and is also an important second-line treatment for advanced bladder cancer (Bellmunt et al., 2017; Balar et al., 2021). This evidence concerns the gene CD274 and urinary bladder carcinoma.